News

Filter

Current filters:

fidaxomicinVaccines

1 to 9 of 95962 results

Chugai and Roche amend business arrangements on out-licensing

Chugai and Roche amend business arrangements on out-licensing

31-08-2014

Japanese drugmaker Chugai has amended the business arrangements with its majority (62%) share-owner Swiss…

Asia-PacificChugai PharmaceuticalEuropeLicensingPharmaceuticalRoche

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

31-08-2014

Swiss drug major Novartis on Saturday presented striking new data for its LZC696 heart drug at the European…

Cardio-vascularLCZ696NovartisPharmaceuticalRegulationResearch

United Thera scores over Sandoz in Remodulin patent case

United Thera scores over Sandoz in Remodulin patent case

31-08-2014

US biotech company United Therapeutics’ shares leapt 28.5% to $117.83 on Friday, after the company…

GenericsLegalNovartisPatentsRemodulinRespiratory and PulmonarySandozUnited TherapeuticsUSA

Positive results from four pivotal alirocumab trials at ESC Congress

Positive results from four pivotal alirocumab trials at ESC Congress

31-08-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have announced detailed positive…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

FTC puts conditions on acquisition of Insight Pharma by Prestige Brands

29-08-2014

US firm Prestige Brands Holdings, the maker of Dramamine (dimenhydrinate), has agreed to divest assets…

Insight PharmaceuticalsMergers & AcquisitionsPharmaceuticalPrestige BrandsRegulationUSA

1 to 9 of 95962 results

Back to top